RxDoctor Payments Data

Samuel Aly, MD

Urology · Shrewsbury, NJNPI 1730574054

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (37.9%), education and food and beverage — rather than concentrated in one kind of arrangement. 42 manufacturers reported payments, led by Boston Scientific at 38.5% of the total. Reporting peaked in 2024 at $9,797 and has fallen 66.3% since, to $3,301 in 2025. Among urology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,883in general payments, 2019–2025

Across 296 payments — averaging $87.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$10K
  • Intuitive Surgical$9K
  • Royal Biologics, Inc.$2K
  • Coloplast$506
  • Davol Inc.$490
  • Astellas Pharma US Inc$411
  • plus $4K from 36 others

What the payments were for

  • Consulting fees$9,80038%
  • Travel & lodging$5812%
  • Food & beverage$7,18428%
  • Education$8,31832%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,883 in reported general payments places this provider in the 90th percentile of 401 urology providers in New Jersey.

See all urology providers in New Jersey

Medicare billing

Part B allowed, 2024
$633,964
Medicare patients
1,015
Services billed
11,940

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron123$76,909
GemtesaVibegron44$55,777
Tamsulosin Hcl380$7,151
Testosterone12$4,939
Solifenacin Succinate73$3,814
Oxybutynin Chloride ErOxybutynin Chloride58$1,215
Finasteride69$935
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst36$806
Ciprofloxacin Hcl64$441
Cephalexin43$252
Alfuzosin Hcl ErAlfuzosin Hcl15$193
Levofloxacin41$159
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen18$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$411$76,909123 claims
Sumitomo Pharma America, Inc.Gemtesa$311$55,77744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 401 urology providers in New Jersey.

Other urology in Shrewsbury

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →